Compare Manhattan Associates Inc (MANH) vs TG Therapeutics Inc (TGTX) Price & Performance

MANH trades at $204.89, up 1.38% on the day, with a bullish technical trend and strong profitability metrics including a 96.38% ROE and 18.67% net income margin. The stock has consistently beaten earnings estimates in recent quarters, though high valuation ratios like a P/E of 59.26 suggest premium pricing. Recent news includes a mix of positive product launches and ongoing legal investigations into fiduciary duties.

The outlook is cautiously optimistic, supported by analyst consensus and solid fundamentals, but risks include the high valuation, potential legal overhangs, and a projected decline in net income for 2026. Upside potential exists toward the $210.50 consensus target if execution remains strong.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.